Background: Although new Pegylated Interferon is available, yet the conventional Interferon with the combination of Ribavirin is still the therapy of choice to treat the Hepatitis C patients. This study was conducted to investigate the response of different HCV genotypes in different age groups of chronic Hepatitis C patients treated with conventional Interferonα-2b (IFNα-2b) plus Ribavirin (RBV).
Methods: In this cross sectional observational study a total of 520 Hepatitis C patients infected with different HCV genotypes meeting the study criteria were included from August 2010 to January 2013. End of treatment response (ETR), sustained virological response (SVR) and the association of patient's age with treatment response were evaluated. ETR and SVR were defined as absence of HCV RNA and normal ALT level at the end of therapy and 12 months after the termination of therapy respectively.
Results: Out of 520 cases 388 (74.62%) showed ETR. The SVR was observed in 290 (89.23%) out of 325 ETR responders. ETR was higher in males (76.14%) than females (72.77%) while the SVR was almost same in both sex. The highest ETR was noted in genotype 3 (81.15%). The old patients exhibited lower ETR and SVR than youngers in the present study.
Conclusions: The properly managed conventional Interferon therapy was effective for Hepatitis C patients infected with genotype 2 and 3 with age <40 years as compared to those patients infected with genotype-1 and 4 or had age >40 years.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Intrahepatic CD161CD8+T Cell Recruitment Has a Pathogenetic Potential in Chronic HBV Infection.
Immun Inflamm Dis
January 2025
Department of Clinical Laboratory, the Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Backgrounds And Aims: CD8+T cells are crucially associated with the fight against hepatitis B virus (HBV) infection. CD161 has been shown to express remarkably on HCV-specific CD8+T cells. However, the accurate function of CD161+CD8+T cells in HBV immunity or pathogenesis remains undetermined.
View Article and Find Full Text PDFThe clinical characteristics and treatment outcomes of patients with systemic polyarteritis nodosa (PAN): a single centre study from India.
Rheumatology (Oxford)
January 2025
Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India.
Objectives: To describe the clinical profile and compare the long-term outcomes of patients with S-PAN treated with various treatment regimens at our centre in the last 2 decades.
Methods: Data regarding clinical presentation, treatment allocation, relapses and outcomes of patients fulfilling American College of Rheumatology (ACR) 1990 criteria for PAN in the last 2 decades were recorded from electronic medical records. Relapse-free survival and predictors were analysed using KM survival statistics and regression analysis.
Association between extracellular matrix protein 1 (ECM1) gene polymorphisms (rs3834087 and rs3754217) and Hepatitis B Virus evolution in an African cohort.
Cell Mol Biol (Noisy-le-grand)
January 2025
Université Joseph KI-ZERBO, Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), 03 BP 7021 Ouagadougou 03, Burkina Faso.
Article Synopsis
- Hepatitis B virus (HBV) is a major global health concern linked to liver disease and cancer, with research focusing on genetic factors that affect its evolution.
- Recent studies highlighted the ECM1 gene, specifically two polymorphisms (rs3834087 and rs3754217), which may influence HBV pathogenesis, particularly in an African cohort analyzed in this research.
- The study found that the heterozygous genotype of rs3754217 appears to protect against chronic hepatitis, suggesting that certain genetic variations may impact the severity of the disease in infected individuals.
Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021.
Hepatol Int
January 2025
Department of Digestive Diseases, Xijing Hospital, Air Force Medical University, Xi'an, 710000, Shaanxi, China.
Background: Liver cancer (LC) is a major concern in the Asia-Pacific region, particularly in China, Korea, and Japan. In this study, we aimed to investigate the burden, trends, and predictions related to LC in these countries.
Methods: Using data from the Global Burden of Disease Study 2021, the epidemiological characteristics [incidence, deaths, and disability-adjusted life-years (DALYs)] for LC were analysed and stratified by specific etiologies in China, Japan, and South Korea.
The effectiveness of two doses of recombinant hepatitis E vaccine in response to an outbreak in Bentiu, South Sudan: a case-control and bias indicator study.
Lancet Infect Dis
January 2025
Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland; Médecins Sans Frontières, Geneva, Switzerland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Geneva, Switzerland. Electronic address:
Background: Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis, particularly in Asia and Africa, where HEV genotypes 1 and 2 are prevalent. Although a recombinant vaccine, Hecolin, is available, it has not been used to control outbreaks. The licensed three-dose regimen might pose challenges for it to be an impactful outbreak control tool.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!